Shaghayegh Haghjooy Javanmard1, Tayebeh Shahsavarzadeh1, Mohammad Saadatnia2. 1. Department of Physiology, Applied Physiology Research Center, Isfahan University of Medical Sciences, Hezar Jerib Avenue, Isfahan, Iran. 2. Department of Neurology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
BACKGROUND: Decreased concentration of tissue factor pathway inhibitor (TFPI) is a risk factor for development of deep venous thrombosis and coronary heart disease, but there is no evidence for the relationship between TFPI and cerebral venous and sinus thrombosis (CVST). The aim of this study was to determine the level of TFPI in healthy population and in patients with CVST. MATERIALS AND METHODS: We determined the plasma level of TFPI in 20 patients with CVST (cases) and 31 healthy volunteer subjects (as control group) by enzyme linked immunoassay method. We also examined the association between TFPI and the risk of CVST. Continuous variables were compared between groups using Student's t test, and odds ratio was calculated by multiple logistic regression analysis. RESULTS: The mean TFPI was significantly lower in the CVST group compared with the control group (8.60 ± 4.05 ng/mL; 14.6 ± 8.6 ng/mL; P = 0. 005), respectively. The odds ratio for CVST associated with low (<25(th) percentile) levels of TFPI was 5.429 (95% CI, 1.487-19.82, P = 0.012). CONCLUSION: Our investigation demonstrates that reduced TFPI may be one of the risk factors of CVST and associated with increasing the risk of developing CVST.
BACKGROUND: Decreased concentration of tissue factor pathway inhibitor (TFPI) is a risk factor for development of deep venous thrombosis and coronary heart disease, but there is no evidence for the relationship between TFPI and cerebral venous and sinus thrombosis (CVST). The aim of this study was to determine the level of TFPI in healthy population and in patients with CVST. MATERIALS AND METHODS: We determined the plasma level of TFPI in 20 patients with CVST (cases) and 31 healthy volunteer subjects (as control group) by enzyme linked immunoassay method. We also examined the association between TFPI and the risk of CVST. Continuous variables were compared between groups using Student's t test, and odds ratio was calculated by multiple logistic regression analysis. RESULTS: The mean TFPI was significantly lower in the CVST group compared with the control group (8.60 ± 4.05 ng/mL; 14.6 ± 8.6 ng/mL; P = 0. 005), respectively. The odds ratio for CVST associated with low (<25(th) percentile) levels of TFPI was 5.429 (95% CI, 1.487-19.82, P = 0.012). CONCLUSION: Our investigation demonstrates that reduced TFPI may be one of the risk factors of CVST and associated with increasing the risk of developing CVST.
Authors: E M Bladbjerg; J S Madsen; S R Kristensen; B Abrahamsen; K Brixen; L Mosekilde; J Jespersen Journal: J Thromb Haemost Date: 2003-06 Impact factor: 5.824
Authors: M Yamamuro; H Wada; K Kumeda; A Inoue; I Tsuji; T Nakasaki; M Shimura; K Hiyoyama; E C Gabazza; M Nishikawa; K Deguchi; H Shiku; H Kato Journal: Blood Coagul Fibrinolysis Date: 1998-09 Impact factor: 1.276
Authors: David A Hinds; Alfonso Buil; Daniel Ziemek; Angel Martinez-Perez; Rainer Malik; Lasse Folkersen; Marine Germain; Anders Mälarstig; Andrew Brown; Jose Manuel Soria; Martin Dichgans; Nan Bing; Anders Franco-Cereceda; Juan Carlos Souto; Emmanouil T Dermitzakis; Anders Hamsten; Bradford B Worrall; Joyce Y Tung; Maria Sabater-Lleal Journal: Hum Mol Genet Date: 2016-02-09 Impact factor: 6.150
Authors: Inge M Rietveld; Mettine H A Bos; Willem M Lijfering; Ruifang Li-Gao; Frits R Rosendaal; Pieter H Reitsma; Suzanne C Cannegieter Journal: Res Pract Thromb Haemost Date: 2018-04-14